Kesimpta® (ofatumumab) – New drug approval
August 20, 2020 - Genmab and Novartis announced the FDA approval of Kesimpta (ofatumumab), for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Top